TY - JOUR
T1 - The right combination – treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in johannesburg, South Africa
AU - Hirasen, Kamban
AU - Evans, Denise
AU - Maskew, Mhairi
AU - Sanne, Ian M.
AU - Shearer, Kate
AU - Govathson, Caroline
AU - Malete, Given
AU - Kluberg, Sheryl A.
AU - Fox, Matthew P.
N1 - Funding Information:
KH, DE, MM, IMS, KS, CG, GM, SAK, and MPF were supported through USAID cooperative agreement number 674-A-12-00029 to the Health Economics and Epidemiology Research Office. Additional support to KS was provided by the National Institutes of Health (T32AI102623).
Funding Information:
This study was made possible by the generous support of the American people through cooperative agreement AID 674-A-12-00029 from the United States Agency for International Development (USAID) South Africa. The contents of the article are the responsibility of the authors and do not necessarily reflect the views of USAID or the US Government. The funders had no role in the study design, collection, analysis, and interpretation of the data; in the writing of the report; approval of the manuscript; or in the decision to submit the paper for publication. KH, DE, MM, IMS, KS, CG, GM, SAK, and MPF were supported through USAID cooperative agreement number 674-A-12-00029 to the Health Economics and Epidemiology Research Office. Additional support to KS was provided by the National Institutes of Health (T32AI102623).
Publisher Copyright:
© 2018 Hirasen et al.
PY - 2018
Y1 - 2018
N2 - Background: Long-term antiretroviral therapy (ART) adherence is critical for achieving optimal HIV treatment outcomes. Fixed-dose combination (FDC) single-pill regimens, introduced in South Africa in April 2013, has simplified pill taking. We evaluated treatment outcomes among patients initiated on a FDC compared to a similar multi-pill ART regimen in Johannesburg, South Africa. Methods: We conducted a retrospective cohort study of ART-naïve HIV-positive non-pregnant adult (≥18 years) patients without tuberculosis who initiated first-line ART on tenofovir and emtricitabine or lamivudine with efavirenz at Themba Lethu Clinic in Johannesburg, South Africa. We compared those initiated on a multi-pill ART regimen (3–5 pills/day; September 1, 2011–August 31, 2012) to those initiated on a FDC ART regimen (one pill/day; September 1, 2013–August 31, 2014). Treatment outcomes included attrition (combination of lost to follow-up and mortality), missed medical visits, and virologic suppression (viral load <400 copies/mL) by 12 months post-ART initiation. Cox proportional hazards models and Poisson regression were used to estimate the association between FDCs vs multiple pills and treatment outcomes. Results: We included 3151 patients in our analysis; 2230 (70.8%) patients initiated multi-pill ART and 921 (29.2%) patients initiated on a FDC. By 12 months post-initiation, attrition (adjusted hazard ratio: 0.98; 95% CI: 0.77–1.24) was similar across regimen types (FDC vs multi-pill). Although not significant, patients on a FDC were marginally more likely to achieve viral suppression by 6 (adjusted relative rate [aRR]: 1.10; 95% CI: 0.99–1.23) and 12 months (aRR: 1.12; 95% CI: 0.92–1.36) on ART. Patients initiated on a FDC were significantly less likely to miss medical visits during the first 12 months of treatment (aRR: 0.66; 95% CI: 0.52–0.83). Conclusion: Our results suggest FDCs may have a role to play in supporting patient adherence and medical monitoring through improved medical visit attendance. This may potentially improve treatment outcomes later on in treatment.
AB - Background: Long-term antiretroviral therapy (ART) adherence is critical for achieving optimal HIV treatment outcomes. Fixed-dose combination (FDC) single-pill regimens, introduced in South Africa in April 2013, has simplified pill taking. We evaluated treatment outcomes among patients initiated on a FDC compared to a similar multi-pill ART regimen in Johannesburg, South Africa. Methods: We conducted a retrospective cohort study of ART-naïve HIV-positive non-pregnant adult (≥18 years) patients without tuberculosis who initiated first-line ART on tenofovir and emtricitabine or lamivudine with efavirenz at Themba Lethu Clinic in Johannesburg, South Africa. We compared those initiated on a multi-pill ART regimen (3–5 pills/day; September 1, 2011–August 31, 2012) to those initiated on a FDC ART regimen (one pill/day; September 1, 2013–August 31, 2014). Treatment outcomes included attrition (combination of lost to follow-up and mortality), missed medical visits, and virologic suppression (viral load <400 copies/mL) by 12 months post-ART initiation. Cox proportional hazards models and Poisson regression were used to estimate the association between FDCs vs multiple pills and treatment outcomes. Results: We included 3151 patients in our analysis; 2230 (70.8%) patients initiated multi-pill ART and 921 (29.2%) patients initiated on a FDC. By 12 months post-initiation, attrition (adjusted hazard ratio: 0.98; 95% CI: 0.77–1.24) was similar across regimen types (FDC vs multi-pill). Although not significant, patients on a FDC were marginally more likely to achieve viral suppression by 6 (adjusted relative rate [aRR]: 1.10; 95% CI: 0.99–1.23) and 12 months (aRR: 1.12; 95% CI: 0.92–1.36) on ART. Patients initiated on a FDC were significantly less likely to miss medical visits during the first 12 months of treatment (aRR: 0.66; 95% CI: 0.52–0.83). Conclusion: Our results suggest FDCs may have a role to play in supporting patient adherence and medical monitoring through improved medical visit attendance. This may potentially improve treatment outcomes later on in treatment.
KW - Adherence
KW - Antiretroviral therapy
KW - Attrition
KW - Fixed-dose combination
KW - South Africa
KW - Virologic suppression
UR - http://www.scopus.com/inward/record.url?scp=85041515981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041515981&partnerID=8YFLogxK
U2 - 10.2147/CLEP.S145983
DO - 10.2147/CLEP.S145983
M3 - Article
AN - SCOPUS:85041515981
VL - 10
SP - 17
EP - 29
JO - Clinical Epidemiology
JF - Clinical Epidemiology
SN - 1179-1349
ER -